157 related articles for article (PubMed ID: 38388922)
21. Relationship between polycomb-group protein BMI-1 and phosphatases regulating AKT phosphorylation level in endometrial cancer.
Zaczek A; Jóźwiak P; Ciesielski P; Forma E; Wójcik-Krowiranda K; Cwonda Ł; Bieńkiewicz A; Bryś M; Krześlak A
J Cell Mol Med; 2020 Jan; 24(2):1300-1310. PubMed ID: 31863623
[TBL] [Abstract][Full Text] [Related]
22. Utility of PTEN expression of endometrial "surface epithelial changes" and underlying atypical endometrial hyperplasia.
Quddus MR; Ologun BA; Sung CJ; Steinhoff MM; Lawrence WD
Int J Gynecol Pathol; 2009 Sep; 28(5):471-6. PubMed ID: 19696618
[TBL] [Abstract][Full Text] [Related]
23. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium.
Erkanli S; Kayaselcuk F; Kuscu E; Bagis T; Bolat F; Haberal A; Demirhan B
Int J Gynecol Cancer; 2006; 16(3):1412-8. PubMed ID: 16803539
[TBL] [Abstract][Full Text] [Related]
24. Immunoexpression of Cyclin D1 and PTEN in Various Endometrial Pathologies.
Shawana S; Kehar SI; Masood S; Aamir I
J Coll Physicians Surg Pak; 2016 Apr; 26(4):277-82. PubMed ID: 27097697
[TBL] [Abstract][Full Text] [Related]
25. Association of mismatch repair deficiency with PTEN frameshift mutations in endometrial cancers and the precursors in a Japanese population.
Kanaya T; Kyo S; Sakaguchi J; Maida Y; Nakamura M; Takakura M; Hashimoto M; Mizumoto Y; Inoue M
Am J Clin Pathol; 2005 Jul; 124(1):89-96. PubMed ID: 15923161
[TBL] [Abstract][Full Text] [Related]
26. Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias.
Konopka B; Paszko Z; Janiec-Jankowska A; Goluda M
Cancer Lett; 2002 Apr; 178(1):43-51. PubMed ID: 11849740
[TBL] [Abstract][Full Text] [Related]
27. Strong correlation between molecular changes in endometrial carcinomas and concomitant hyperplasia.
Zauber P; Denehy TR; Taylor RR; Ongcapin EH; Marotta S; Sabbath-Solitare M
Int J Gynecol Cancer; 2015 Jun; 25(5):863-8. PubMed ID: 25768080
[TBL] [Abstract][Full Text] [Related]
28. Critical tumor suppressor function mediated by epithelial Mig-6 in endometrial cancer.
Kim TH; Lee DK; Cho SN; Orvis GD; Behringer RR; Lydon JP; Ku BJ; McCampbell AS; Broaddus RR; Jeong JW
Cancer Res; 2013 Aug; 73(16):5090-9. PubMed ID: 23811943
[TBL] [Abstract][Full Text] [Related]
29. Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression.
Baak JP; Van Diermen B; Steinbakk A; Janssen E; Skaland I; Mutter GL; Fiane B; Løvslett K
Hum Pathol; 2005 May; 36(5):555-61. PubMed ID: 15948123
[TBL] [Abstract][Full Text] [Related]
30. Assessing the prognostic value of PAX2 and PTEN in endometrial carcinogenesis.
Rewcastle E; Varhaugvik AE; Gudlaugsson E; Steinbakk A; Skaland I; van Diermen B; Baak JP; Janssen EAM
Endocr Relat Cancer; 2018 Dec; 25(12):981-991. PubMed ID: 30400021
[TBL] [Abstract][Full Text] [Related]
31. PTEN sequence analysis in endometrial hyperplasia and endometrial carcinoma in Slovak women.
Gbelcová H; Bakeš P; Priščáková P; Šišovský V; Hojsíková I; Straka Ľ; Konečný M; Markus J; D'Acunto CW; Ruml T; Böhmer D; Danihel Ľ; Repiská V
Anal Cell Pathol (Amst); 2015; 2015():746856. PubMed ID: 26114084
[TBL] [Abstract][Full Text] [Related]
32. MLH1 and MSH2 protein expression as a pre-screening marker in hereditary and non-hereditary endometrial hyperplasia and cancer.
Berends MJ; Hollema H; Wu Y; van Der Sluis T; Mensink RG; ten Hoor KA; Sijmons RH; de Vries EG; Pras E; Mourits MJ; Hofstra RM; Buys CH; Kleibeuker JH; van Der Zee AG
Int J Cancer; 2001 May; 92(3):398-403. PubMed ID: 11291077
[TBL] [Abstract][Full Text] [Related]
33. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
[TBL] [Abstract][Full Text] [Related]
34. Mig-6 Mouse Model of Endometrial Cancer.
Kim TH; Yoo JY; Jeong JW
Adv Exp Med Biol; 2017; 943():243-259. PubMed ID: 27910070
[TBL] [Abstract][Full Text] [Related]
35. Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice.
Bajwa P; Nielsen S; Lombard JM; Rassam L; Nahar P; Rueda BR; Wilkinson JE; Miller RA; Tanwar PS
Oncotarget; 2017 Jan; 8(5):7265-7275. PubMed ID: 27980219
[TBL] [Abstract][Full Text] [Related]
36. [Morphological diagnosis of endometrial intraepithelial neoplasia and expression of PTEN].
Zhou WX; Liang ZY; Gao J; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2009 Jun; 38(6):393-6. PubMed ID: 19781346
[TBL] [Abstract][Full Text] [Related]
37. Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.
Malentacchi F; Turrini I; Sorbi F; Projetto E; Castiglione F; Fambrini M; Petraglia F; Pillozzi S; Noci I
Oncol Rep; 2019 Mar; 41(3):1560-1574. PubMed ID: 30569174
[TBL] [Abstract][Full Text] [Related]
38. Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease.
Jeong JW; Lee HS; Lee KY; White LD; Broaddus RR; Zhang YW; Vande Woude GF; Giudice LC; Young SL; Lessey BA; Tsai SY; Lydon JP; DeMayo FJ
Proc Natl Acad Sci U S A; 2009 May; 106(21):8677-82. PubMed ID: 19439667
[TBL] [Abstract][Full Text] [Related]
39. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
[TBL] [Abstract][Full Text] [Related]
40. Expression of miRNAs and PTEN in endometrial specimens ranging from histologically normal to hyperplasia and endometrial adenocarcinoma.
Lee H; Choi HJ; Kang CS; Lee HJ; Lee WS; Park CS
Mod Pathol; 2012 Nov; 25(11):1508-15. PubMed ID: 22766795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
